These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3770 related articles for article (PubMed ID: 29968072)

  • 1. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
    Bartha E; Solti I; Kereskai L; Lantos J; Plozer E; Magyar K; Szabados E; Kálai T; Hideg K; Halmosi R; Sumegi B; Toth K
    Cardiovasc Res; 2009 Aug; 83(3):501-10. PubMed ID: 19443425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
    Pacher P; Szabó C
    Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration.
    Kaplan J; O'Connor M; Hake PW; Zingarelli B
    Shock; 2005 Mar; 23(3):233-8. PubMed ID: 15718920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
    Qin WD; Liu GL; Wang J; Wang H; Zhang JN; Zhang F; Ma Y; Ji XY; Li C; Zhang MX
    Oncotarget; 2016 Jun; 7(24):35618-35631. PubMed ID: 27027354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock.
    Evgenov OV; Liaudet L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):293-9. PubMed ID: 16026325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal trauma model: in search of Thanatos.
    Cole K; Perez-Polo JR
    Int J Dev Neurosci; 2004 Nov; 22(7):485-96. PubMed ID: 15465278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
    Skaper SD
    Ann N Y Acad Sci; 2003 May; 993():217-28; discussion 287-8. PubMed ID: 12853316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
    Erdélyi K; Bakondi E; Gergely P; Szabó C; Virág L
    Cell Mol Life Sci; 2005 Apr; 62(7-8):751-9. PubMed ID: 15868400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.
    Halmosi R; Berente Z; Osz E; Toth K; Literati-Nagy P; Sumegi B
    Mol Pharmacol; 2001 Jun; 59(6):1497-505. PubMed ID: 11353811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
    Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
    J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability.
    Hans CP; Zerfaoui M; Naura AS; Catling A; Boulares AH
    Cardiovasc Res; 2008 Jun; 78(3):429-39. PubMed ID: 18245064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.
    Mathews MT; Berk BC
    Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):711-7. PubMed ID: 18239155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
    Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
    Beneke S; Diefenbach J; Bürkle A
    Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension.
    Kaur G; Singh N; Lingeshwar P; Siddiqui HH; Hanif K
    Pulm Pharmacol Ther; 2015 Feb; 30():66-79. PubMed ID: 25481773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
    Qin WD; Wei SJ; Wang XP; Wang J; Wang WK; Liu F; Gong L; Yan F; Zhang Y; Zhang M
    Biochim Biophys Acta; 2013 Jan; 1833(1):59-68. PubMed ID: 23085506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
    Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
    Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 189.